Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
EU class 3 compression hosiery vs no compression Duration of reulceration episodes · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | no estimate extracted | 2000 participants | Ungraded |
UK class 2 compression hosiery vs UK class 3 compression hosiery Comfort · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | no estimate extracted | NR | No studies |
UK class 2 compression hosiery vs UK class 3 compression hosiery Adverse effects · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Reulceration · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | RR 0.77 [0.47, 1.28] | 1 study · 166 participants | Low |
Intervention NR Duration of reulceration episodes · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | no estimate extracted | 1995 participants | Ungraded |
Intervention NR Proportion of · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | no estimate extracted | 1995 participants | Ungraded |
Intervention NR Ulceration on the contralateral leg · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | no estimate extracted | 1995 participants | Ungraded |
Intervention NR Noncompliance · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | RR 0.97 [0.84, 1.12] | 1 study · 166 participants | Low |
Intervention NR Comfort · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | no estimate extracted | 1995 participants | Ungraded |
Intervention NR Adverse effects · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | no estimate extracted | 1995 participants | Ungraded |
EU class 3 compression hosiery vs no compression Proportion of · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | no estimate extracted | 2000 participants | Ungraded |
EU class 3 compression hosiery vs no compression Ulceration on the contralateral leg · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | no estimate extracted | 2000 participants | Ungraded |
EU class 3 compression hosiery vs no compression Noncompliance · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | no estimate extracted | 2000 participants | Ungraded |
EU class 3 compression hosiery vs no compression Comfort · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | no estimate extracted | 2000 participants | Ungraded |
EU class 3 compression hosiery vs no compression Adverse effects · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | no estimate extracted | 2000 participants | Ungraded |
EU class 1 compression hosiery vs EU class 2 compression hosiery Reulceration · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | RR 1.7 [0.67, 4.32] | 1 study · 99 participants | Low |
EU class 1 compression hosiery vs EU class 2 compression hosiery Duration of reulceration episodes · people with healed venous leg ulcers Compression for preventing recurrence of venous ulcers (2024) · Cochrane | no estimate extracted | 2014 participants | Ungraded |
Methotrexate vs placebo Outcomes(time frame of absolute effects) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Treatment responsea · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Sustained clinically inactive diseaseb(12 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 1.37 [0.91, 2.06] | 1 study · 207 participants | Low |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Function · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Pain · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Participant global assessment of well‐being · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Serious adverse events(12 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | Very low |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Withdrawals due to adverse events(12 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 8.75 [0.48, 160.4] | 1 study · 207 participants | Low |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Outcomes(time frame of absolute effects) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Treatment responsea(4 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 1.4 [0.93, 2.1] | 1 study · 94 participants | Low |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Sustained clinically inactive diseasec · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs placebo Treatment responsea(up to 6 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 1.67 [1.21, 2.31] | 3 studies · 328 participants | Low |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Function · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | 1 study · 94 participants | Low |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Pain · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Participant global assessment of well‐being · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | 1 study · 94 participants | Low |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Serious adverse events(4 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 0.14 [0.01, 2.69] | 1 study · 94 participants | Low |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Withdrawals due to adverse events(4 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 0.33 [0.04, 3.09] | 1 study · 94 participants | Low |
Methotrexate vs placebo Sustained clinically inactive diseasec · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs placebo Function · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs placebo Pain Mean improvement in pain on motion from baseline, 0–100 scale, 0 represents no pain(up to 6 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | 1 study · 114 participants | Low |
Methotrexate vs placebo Participant global assessment of well‐being(up to 6 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 1.23 [0.88, 1.72] | 1 study · 176 participants | Low |
Methotrexate vs placebo Serious adverse events(up to 6 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 0.63 [0.04, 8.97] | 3 studies · 328 participants | Low |
Methotrexate vs placebo Withdrawals due to adverse events (up to 6 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 3.46 [0.6, 19.79] | 3 studies · 328 participants | Low |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Outcomes(time frame of absolute effects) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Salbutamol vs placebo Mortality within the trial period · preterm infants (< 37 weeks GA) at risk of chronic lung disease Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants (2024) · Cochrane | RR 1.08 [0.5, 2.31] | 1 study · 173 participants | Low |
Summary of findings table ‐ Salbutamol vs placebo Chronic lung disease at 28 days · preterm infants (< 37 weeks GA) at risk of chronic lung disease Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants (2024) · Cochrane | RR 1.03 [0.78, 1.37] | 1 study · 173 participants | Low |
Summary of findings table ‐ Salbutamol vs placebo Adverse effects of bronchodilators, including hypokalaemia, tachycardia, cardiac arrhythmia, tremor, hypertension and hyperglycaemia ‐ not reported · preterm infants (< 37 weeks GA) at risk of chronic lung disease Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Salbutamol vs placebo Pneumothorax · preterm infants (< 37 weeks GA) at risk of chronic lung disease Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants (2024) · Cochrane | no estimate extracted | 1 study · 173 participants | Very low |
Summary of findings table ‐ Energy, protein and micronutrients vs standard diet Incidence of pressure ulcers · inpatients who are mildly or seriously malnourished or at risk of being malnourished, elderly patients at risk of… Nutritional interventions for preventing and treating pressure ulcers (2024) · Cochrane | RR 0.92 [0.71, 1.19] | 3 studies · 1634 participants | Low |
Summary of findings table ‐ Protein vs standard diet Side effects: at least one adverse gastrointestinal event · patients (> 65 years) following hip fracture; patients with a recent stroke Nutritional interventions for preventing and treating pressure ulcers (2024) · Cochrane | RR 0.7 [0.06, 7.96] | 2 studies · 140 participants | Very low |
Summary of findings table ‐ Protein vs standard diet Costs ‐ not reported · patients (> 65 years) following hip fracture; patients with a recent stroke Nutritional interventions for preventing and treating pressure ulcers (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Protein vs standard diet Health‐related quality of life ‐ not reported · patients (> 65 years) following hip fracture; patients with a recent stroke Nutritional interventions for preventing and treating pressure ulcers (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Energy, protein and micronutrients vs standard diet Pressure ulcers healed · long‐term care patients; inpatients without dehydration with energy intake by tube feeding; patients with pressure… Nutritional interventions for preventing and treating pressure ulcers (2024) · Cochrane | RR 1.45 [1.14, 1.85] | 3 studies · 577 participants | Low |